Ritu Baral
Stock Analyst at TD Cowen
(2.99)
# 1,342
Out of 5,238 analysts
45
Total ratings
41.46%
Success rate
3.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HELP Cybin | Initiates: Buy | $8 | $5.31 | +50.66% | 1 | Apr 13, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $37 | $22.40 | +65.18% | 3 | Feb 26, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $202 → $306 | $305.71 | +0.09% | 1 | Jan 9, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $67 | $30.68 | +118.38% | 1 | Jan 5, 2026 | |
| INSM Insmed | Maintains: Buy | $269 → $241 | $101.35 | +137.79% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $97 → $133 | $121.29 | +9.65% | 3 | Dec 16, 2025 | |
| MIST Milestone Pharmaceuticals | Upgrades: Buy | $8 | $1.92 | +316.67% | 1 | Dec 15, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $251 → $353 | $330.02 | +6.96% | 1 | Dec 8, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $36.19 | +101.71% | 2 | Dec 5, 2025 | |
| RNA Atrium Therapeutics | Downgrades: Hold | $78 → $74 | $13.07 | +466.18% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $390 → $554 | $510.04 | +8.62% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.56 | - | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.46 | - | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $282 → $371 | $295.05 | +25.74% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.71 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $19.96 | +776.97% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $56.50 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.38 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.42 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.03 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.22 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $403.54 | - | 2 | Jan 12, 2018 |
Cybin
Apr 13, 2026
Initiates: Buy
Price Target: $8
Current: $5.31
Upside: +50.66%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $35 → $37
Current: $22.40
Upside: +65.18%
Krystal Biotech
Jan 9, 2026
Maintains: Buy
Price Target: $202 → $306
Current: $305.71
Upside: +0.09%
vTv Therapeutics
Jan 5, 2026
Initiates: Buy
Price Target: $67
Current: $30.68
Upside: +118.38%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $269 → $241
Current: $101.35
Upside: +137.79%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $97 → $133
Current: $121.29
Upside: +9.65%
Milestone Pharmaceuticals
Dec 15, 2025
Upgrades: Buy
Price Target: $8
Current: $1.92
Upside: +316.67%
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $251 → $353
Current: $330.02
Upside: +6.96%
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $36.19
Upside: +101.71%
Atrium Therapeutics
Oct 29, 2025
Downgrades: Hold
Price Target: $78 → $74
Current: $13.07
Upside: +466.18%
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $510.04
Upside: +8.62%
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.56
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.46
Upside: -
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $295.05
Upside: +25.74%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $7.71
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $19.96
Upside: +776.97%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $56.50
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.38
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.42
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.03
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.22
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $403.54
Upside: -